Noriko Aida

Noriko Aida

Auto-generated profile, based on publicly available information

Noriko Aida

Department of Radiology, Kanagawa Children’s Medical Center

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2013 in neurogenetics
Verified
Journal Article
Closed access
PDF file
COChihiro Ohba
Chihiro Ohba
HOHitoshi Osaka
Hitoshi Osaka
MIMizue Iai
Mizue Iai
SYSumimasa Yamashita
Sumimasa Yamashita
YSYume Suzuki
Yume Suzuki
HSHirotomo Saitsu
Hirotomo Saitsu

1 January 2022 in Magnetic Resonance in Medical Sciences
Verified
Journal Article
Open access
PDF file
NANoriko Aida
Noriko Aida
MRI interpretations of the pediatric brain are often challenging for general radiologists and clinicians because MR signals and morphology are continuously changing in the developing brain. Furthermore, the developing brain reacts differently to injuries, resulting in imaging characteristics that differ from those of the mature brain. Proton magnetic resonance spectroscopy (1H-MRS) is a non-invasive method for assessing neurological abnormalities at the microscopic level and measures in vivo brain metabolites using a clinical MR machine. In MR examinations of the pediatric brain, 1H-MRS demonstrates its powerful diagnostic capability when MRI is insufficient for diagnostic features. MRI and 1H-MRS may be complementary tools for diagnosing and monitoring diseases. However, there is currently no consensus on how to include 1H-MRS in clinical MR examinations. An overview of the clinical implementation of 1H-MRS for the assessment of early pediatric developmental brains as well as the diagnosis, prognostification, and disease monitoring of various non-neoplastic brain disorders, including neonatal encephalopathies and neurometabolic/neurodegenerative diseases, was provided herein. Qualitative and quantitative 1H-MRS is a powerful non-invasive tool for accessing various brain metabolites to confirm age appropriate peaks and detect abnormal peaks or deficient or reduced peaks, which may facilitate the identification of metabolic and neurodegenerative disorders as well as damage associated with hypoxic-ischemic encephalopathy (HIE). Moreover, 1H-MRS has potential as a biomarker for monitoring therapeutic efficacy in metabolic diseases and neonatal HIE. It also provides insights into the pathophysiologies of various disorders, which may facilitate the use of novel therapeutic approaches. Therefore, 1H-MRS needs to be included more frequently in routine clinical MR examinations of pediatric patients with neurological disorders.

11 September 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KOKazumasa Odagiri
Kazumasa Odagiri
MOMotoko Omura
Motoko Omura
MHMasaharu Hata
Masaharu Hata
NANoriko Aida
Noriko Aida
TNTetsu Niwa
Tetsu Niwa
TITomio Inoue
Tomio Inoue
Standard treatment strategies for embryonal central nervous system (CNS) tumors have not yet been established. We treated these tumors using an original chemoradiation therapy protocol; the clinical outcomes and toxicities were retrospectively evaluated. Twenty-four patients were enrolled including sixteen with medulloblastoma, four with supratentorial primitive neuroectodermal tumor (sPNET), three with atypical teratoid/rhabdoid tumor, and one with pineoblastoma. Immediately after diagnosis, all patients underwent surgery initially. They were then categorized as high- or average-risk groups independent of tumor type/pathogenesis. The average-risk group included patients who were aged ≥3 years at diagnosis, had non-metastatic disease at diagnosis (M0), and had undergone gross total resection. Other patients were categorized as the high-risk group; this group received more intensive treatment than the average-risk group, including high-dose chemotherapy with autologous stem-cell transplantation. All patients received craniospinal irradiation (CSI). The CSI dose was 23.4 Gy for M0 patients aged ≥5 years, 18 Gy for M0 patients aged <5 years, and 30–36 Gy for all patients with M + disease. The total dose to the primary tumor bed was 54 Gy. The median follow-up time was 73.5 (range, 19–118) months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 71.1 and 88.9%, respectively in the average-risk group (n = 9) and 66.7 and 71.1%, respectively in the high-risk group (n = 15). The PFS and OS rates were not significantly different between the average- and high-risk groups. In patients with medulloblastoma only, these rates were also not significantly different between the average- and high-risk groups. Three of four patients with sPNET were disease free. The height standard deviation score (SDS) was significantly decreased at the last assessment relative to that at diagnosis (P < 0.0001). The latest median height SDS was -1.6 (range, 0.9 to -4.8), and the latest median full-scale intelligence quotient (FSIQ) score was 86 (range, 59–128). The CSI doses and age at the start of radiation therapy did not influence clinical outcomes, height SDSs, and FSIQ scores. Our original protocol for patients with embryonal CNS tumors was feasible and yielded favorable clinical outcomes.

1 November 2016 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
MTMoyoko Tomiyasu
Moyoko Tomiyasu
NANoriko Aida
Noriko Aida
JSJun Shibasaki
Jun Shibasaki
YTYasuhiko Tachibana
Yasuhiko Tachibana
MEMamiko Endo
Mamiko Endo
TOTakayuki Obata
Takayuki Obata

11 May 2006 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
TYToshiyuki Yamamoto
Toshiyuki Yamamoto
KSKiyoko Sameshima
Kiyoko Sameshima
KSKen‐Ichi Sekido
Ken‐Ichi Sekido
NANoriko Aida
Noriko Aida
NMNaomichi Matsumoto
Naomichi Matsumoto
KKKenji Kurosawa
Kenji Kurosawa

1 January 2012
Verified
Journal Article
Closed access
YWYoshihiro Watanabe
Yoshihiro Watanabe
MTMegumi Tsuji
Megumi Tsuji
KSKiyoko Sameshima
Kiyoko Sameshima
TWTakahito Wada
Takahito Wada
MIMizue Iai
Mizue Iai
HOHitoshi Osaka
Hitoshi Osaka